%0 Journal Article
%A Lund, Sophie
%A Gong, Chun
%A Yu, Xin
%A Staudt, Louis M
%A Hodson, Daniel J
%A Scheich, Sebastian
%T Strategies for CRISPR-based knock-ins in primary human B cells and lymphoma cell lines.
%J Frontiers in immunology
%V 16
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2025-01131
%P 1589729
%D 2025
%X Since its advent about ten years ago, the CRISPR-Cas9 system has been frequently used in biomedical applications. It has advanced various fields, and CRISPR-Cas9-based therapeutics have shown promising results in the treatment of specific hematological diseases. Furthermore, CRISPR gene editing technologies have revolutionized cancer research by enabling a broad range of genetic perturbations, including genetic knockouts and precise single nucleotide changes. This perspective focuses on the state-of-the-art methodology of CRISPR knock-ins to engineer immune cells. Since this technique relies on homology-directed repair (HDR) of double-strand breaks (DSBs) induced by the Cas9 enzyme, it can be used to introduce specific mutations into the target genome. Therefore, this methodology offers a valuable opportunity to functionally study specific mutations and to uncover their impacts not only on overall cell functions but also on the mechanisms behind cancer-related alterations in common signaling pathways. This article highlights CRISPR knock-in strategies, protocols, and applications in cancer and immune research, with a focus on diffuse large B cell lymphoma.
%K Humans
%K CRISPR-Cas Systems
%K Gene Knock-In Techniques: methods
%K Gene Editing: methods
%K B-Lymphocytes: metabolism
%K B-Lymphocytes: immunology
%K Cell Line, Tumor
%K Lymphoma, Large B-Cell, Diffuse: genetics
%K DLBCL (Other)
%K NF-kappa B (NF-KB) (Other)
%K gene editing (CRISPR/Cas9) (Other)
%K knock-in (Other)
%K lymphoma (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40453079
%2 pmc:PMC12122508
%R 10.3389/fimmu.2025.1589729
%U https://inrepo02.dkfz.de/record/301747